Sangamo Biosciences, Inc. (NASDAQ:SGMO)

CAPS Rating: 4 out of 5

The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes.

Featured Broker Partners


Advertisement